{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:05:22Z","timestamp":1761843922499,"version":"build-2065373602"},"reference-count":73,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.arcmed.2009.07.003","type":"journal-article","created":{"date-parts":[[2009,9,6]],"date-time":"2009-09-06T04:03:55Z","timestamp":1252209835000},"page":"493-498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Therapeutic Vaccine: Is it Feasible?"],"prefix":"10.1016","volume":"40","author":[{"given":"Lutz","family":"Gissmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2009.07.003_bib1","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ijc.2910400506","article-title":"Interferon treatment of human genital papillomavirus infection: importance of viral type","volume":"40","author":"Schneider","year":"1987","journal-title":"Int J Cancer"},{"key":"10.1016\/j.arcmed.2009.07.003_bib2","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.4049\/jimmunol.178.5.3186","article-title":"TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16","volume":"178","author":"Hasan","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.arcmed.2009.07.003_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1359-6101(00)00023-X","article-title":"Control of interferon signaling in human papillomavirus infection","volume":"12","author":"Koromilas","year":"2001","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.arcmed.2009.07.003_bib4","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.4049\/jimmunol.169.6.3242","article-title":"Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses","volume":"169","author":"Fausch","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.arcmed.2009.07.003_bib5","doi-asserted-by":"crossref","first-page":"8378","DOI":"10.1128\/JVI.77.15.8378-8385.2003","article-title":"Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin","volume":"77","author":"Matthews","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.arcmed.2009.07.003_bib6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1743-422X-4-116","article-title":"The E5 protein of the human papillomavirus type 16 down-regulates HLA-I surface expression in calnexin-expressing but not in calnexin-deficient cells","volume":"4","author":"Gruener","year":"2007","journal-title":"Virol J"},{"key":"10.1016\/j.arcmed.2009.07.003_bib7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/jnci\/dji073","article-title":"Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women","volume":"97","author":"Strickler","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.arcmed.2009.07.003_bib8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0065-230X(01)82007-8","article-title":"Immunity to oncogenic human papillomaviruses","volume":"82","author":"Konya","year":"2001","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.arcmed.2009.07.003_bib9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1128\/CDLI.8.2.209-220.2001","article-title":"Cell-mediated immune response to human papillomavirus infection","volume":"8","author":"Scott","year":"2001","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.arcmed.2009.07.003_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1386-6532(00)00128-1","article-title":"Natural HPV immunity and vaccination strategies","volume":"19","author":"Stern","year":"2000","journal-title":"J Clin Virol"},{"key":"10.1016\/j.arcmed.2009.07.003_bib11","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/1097-0142(19860915)58:6<1246::AID-CNCR2820580612>3.0.CO;2-E","article-title":"Immunohistologic analysis of the phenomenon of spontaneous regression of numerous flat warts","volume":"58","author":"Aiba","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.arcmed.2009.07.003_bib12","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/ajcp\/102.6.768","article-title":"Immunological events in regressing genital warts","volume":"102","author":"Coleman","year":"1994","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.arcmed.2009.07.003_bib13","first-page":"425","article-title":"Correlation between mRNA levels of IL-6 and TNF alpha and progression rate in anal squamous epithelial lesions from HIV-positive men","volume":"21","author":"Arany","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1016\/j.arcmed.2009.07.003_bib14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0166-3542(99)00033-9","article-title":"Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%","volume":"43","author":"Arany","year":"1999","journal-title":"Antiviral Res"},{"key":"10.1016\/j.arcmed.2009.07.003_bib15","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ni758","article-title":"Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway","volume":"3","author":"Hemmi","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.arcmed.2009.07.003_bib16","series-title":"The Epidemiology of Human Papillomavirus and Cervical Cancer","first-page":"147","article-title":"Serological assays for the detection of HPV antibodies","author":"Galloway","year":"1992"},{"key":"10.1016\/j.arcmed.2009.07.003_bib17","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/jnci\/81.22.1698","article-title":"Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer","volume":"81","author":"Jochmus-Kudielka","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.arcmed.2009.07.003_bib18","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1128\/JCM.36.2.475-480.1998","article-title":"Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer","volume":"36","author":"Meschede","year":"1998","journal-title":"J Clin Microbiol"},{"issue":"Pt 6","key":"10.1016\/j.arcmed.2009.07.003_bib19","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1099\/0022-1317-74-6-945","article-title":"Prophylactic and therapeutic vaccination against a mucosal papillomavirus","volume":"74","author":"Campo","year":"1993","journal-title":"J Gen Virol"},{"key":"10.1016\/j.arcmed.2009.07.003_bib20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0042-6822(91)90819-W","article-title":"Studies on vaccination against papillomaviruses: prophylactic and therapeutic vaccination with recombinant structural proteins","volume":"184","author":"Jarrett","year":"1991","journal-title":"Virology"},{"key":"10.1016\/j.arcmed.2009.07.003_bib21","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0264-410X(99)00351-5","article-title":"HPV6b virus like particles are potent immunogens without adjuvant in man","volume":"18","author":"Zhang","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.arcmed.2009.07.003_bib22","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0140-6736(96)90674-1","article-title":"A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer","volume":"347","author":"Borysiewicz","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.arcmed.2009.07.003_bib23","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/eji.1830230929","article-title":"Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells","volume":"23","author":"Feltkamp","year":"1993","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.arcmed.2009.07.003_bib24","doi-asserted-by":"crossref","first-page":"11451","DOI":"10.1128\/JVI.78.21.11451-11460.2004","article-title":"Mechanisms of human papillomavirus-induced oncogenesis","volume":"78","author":"Munger","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.arcmed.2009.07.003_bib25","series-title":"The Vaccine Book","first-page":"311","article-title":"Human papillomaviruses","author":"Gissmann","year":"2003"},{"key":"10.1016\/j.arcmed.2009.07.003_bib26","doi-asserted-by":"crossref","first-page":"s333","DOI":"10.2741\/1003","article-title":"A review of human papillomavirus vaccines: from basic science to clinical trials","volume":"8","author":"Berry","year":"2003","journal-title":"Front Biosci"},{"key":"10.1016\/j.arcmed.2009.07.003_bib27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/088282403322017866","article-title":"Cervical cancer vaccines: recent advances in HPV research","volume":"16","author":"Eiben","year":"2003","journal-title":"Viral Immunol"},{"key":"10.1016\/j.arcmed.2009.07.003_bib28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00000441-199507000-00006","article-title":"Effect of interferon therapy on human papillomavirus copy number in patients with condyloma acuminatum","volume":"310","author":"Arany","year":"1995","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.arcmed.2009.07.003_bib29","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1503\/cmaj.070948","article-title":"Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials","volume":"177","author":"Rambout","year":"2007","journal-title":"CMAJ"},{"key":"10.1016\/j.arcmed.2009.07.003_bib30","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.arcmed.2009.07.003_bib31","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/sj.onc.1210791","article-title":"Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts","volume":"27","author":"Hafner","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.arcmed.2009.07.003_bib32","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1128\/JVI.77.2.1551-1563.2003","article-title":"Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells","volume":"77","author":"DeFilippis","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.arcmed.2009.07.003_bib33","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.1038\/sj.onc.1206894","article-title":"siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells","volume":"22","author":"Butz","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.arcmed.2009.07.003_bib34","series-title":"Modern Uterine Cytopathology","first-page":"169","article-title":"Human papillomavirus vaccines","author":"Gissmann","year":"2007"},{"key":"10.1016\/j.arcmed.2009.07.003_bib35","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ijc.23252","article-title":"Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions","volume":"122","author":"Kanodia","year":"2008","journal-title":"Int J\u00a0Cancer"},{"key":"10.1016\/j.arcmed.2009.07.003_bib36","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/sj.gt.3301257","article-title":"Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7","volume":"7","author":"Daemen","year":"2000","journal-title":"Gene Ther"},{"key":"10.1016\/j.arcmed.2009.07.003_bib37","first-page":"3676","article-title":"Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer","volume":"8","author":"Kaufmann","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2009.07.003_bib38","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0140-6736(91)91014-L","article-title":"Skin test for HPV type 16 proteins in cervical intraepithelial neoplasia","volume":"337","author":"Hopfl","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.arcmed.2009.07.003_bib39","first-page":"1229","article-title":"Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX","volume":"12","author":"Hariharan","year":"1998","journal-title":"Int J Oncol"},{"key":"10.1016\/j.arcmed.2009.07.003_bib40","first-page":"7234","article-title":"Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6\/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection","volume":"62","author":"Kim","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.arcmed.2009.07.003_bib41","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1016\/S0264-410X(00)00488-6","article-title":"Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer","volume":"19","author":"Adams","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.arcmed.2009.07.003_bib42","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00262-004-0501-4","article-title":"Phase I\/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia","volume":"53","author":"Hallez","year":"2004","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.arcmed.2009.07.003_bib43","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1016\/j.vaccine.2004.03.057","article-title":"Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin","volume":"22","author":"Hsieh","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.arcmed.2009.07.003_bib44","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s10350-004-6229-6","article-title":"Activity of HspE7, a novel immunotherapy, in patients with anogenital warts","volume":"45","author":"Goldstone","year":"2002","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.arcmed.2009.07.003_bib45","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/ijc.23022","article-title":"Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2\/3)","volume":"121","author":"Kaufmann","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.arcmed.2009.07.003_bib46","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1073\/pnas.95.4.1800","article-title":"Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model","volume":"95","author":"Greenstone","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.arcmed.2009.07.003_bib47","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1128\/JVI.02726-07","article-title":"Arrangement of L2 within the papillomavirus capsid","volume":"82","author":"Buck","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.arcmed.2009.07.003_bib48","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/(SICI)1097-0215(19990611)81:6<881::AID-IJC8>3.0.CO;2-T","article-title":"Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection","volume":"81","author":"Sch\u00e4fer","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.arcmed.2009.07.003_bib49","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1016\/S0264-410X(02)00350-X","article-title":"Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an\u00a0HPV16 L2E7E6 fusion protein vaccine","volume":"20","author":"de Jong","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.arcmed.2009.07.003_bib50","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1517\/14712598.4.2.181","article-title":"Peptide-based vaccines for cancer immunotherapy","volume":"4","author":"Brinkman","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.arcmed.2009.07.003_bib51","first-page":"3406","article-title":"A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive","volume":"6","author":"Muderspach","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2009.07.003_bib52","first-page":"2103","article-title":"Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7","volume":"4","author":"Steller","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2009.07.003_bib53","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0959-8049(99)00048-9","article-title":"Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial","volume":"35","author":"van Driel","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.arcmed.2009.07.003_bib54","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.2741\/salit","article-title":"Ins and outs of clinical trials with peptide-based vaccines","volume":"7","author":"Salit","year":"2002","journal-title":"Front Biosci"},{"key":"10.1016\/j.arcmed.2009.07.003_bib55","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4049\/jimmunol.169.1.350","article-title":"Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides","volume":"169","author":"Zwaveling","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.arcmed.2009.07.003_bib56","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1158\/1078-0432.CCR-07-1881","article-title":"Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity","volume":"14","author":"Kenter","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2009.07.003_bib57","first-page":"1028","article-title":"Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101","volume":"8","author":"Klencke","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2009.07.003_bib58","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nm0398-365","article-title":"Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses","volume":"4","author":"Hedley","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.arcmed.2009.07.003_bib59","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0042-6822(91)90470-V","article-title":"Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7","volume":"181","author":"Meneguzzi","year":"1991","journal-title":"Virology"},{"key":"10.1016\/j.arcmed.2009.07.003_bib60","first-page":"6032","article-title":"Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16\/18 oncoproteins","volume":"63","author":"Davidson","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.arcmed.2009.07.003_bib61","first-page":"5205","article-title":"Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia","volume":"9","author":"Baldwin","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2009.07.003_bib62","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1089\/10430340460745757","article-title":"Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus","volume":"15","author":"Corona Gutierrez","year":"2004","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.arcmed.2009.07.003_bib63","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1158\/1078-0432.CCR-03-0703","article-title":"Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination","volume":"10","author":"Smyth","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2009.07.003_bib64","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1586\/14760584.7.7.889","article-title":"Clinical development of MVA-based therapeutic cancer vaccines","volume":"7","author":"Acres","year":"2008","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.arcmed.2009.07.003_bib65","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.vaccine.2003.07.003","article-title":"Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes","volume":"22","author":"Cassetti","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.arcmed.2009.07.003_bib66","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1006\/viro.2000.0717","article-title":"Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice","volume":"279","author":"Revaz","year":"2001","journal-title":"Virology"},{"key":"10.1016\/j.arcmed.2009.07.003_bib67","first-page":"724","article-title":"Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells","volume":"58","author":"De Bruijn","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.arcmed.2009.07.003_bib68","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/135965350400900419","article-title":"Activation of dendritic cells and induction of T cell responses by HPV 16 L1\/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol","volume":"9","author":"Freyschmidt","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1016\/j.arcmed.2009.07.003_bib69","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/978-1-4757-9966-8_94","article-title":"Generation of in vitro autologous human cytotoxic T-cell response to E7 and HER-2\/neu oncogene products using ex-vivo peptide loaded dendritic cells","volume":"417","author":"Navabi","year":"1997","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.arcmed.2009.07.003_bib70","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/1097-0215(200102)9999:9999<::AID-IJC1181>3.0.CO;2-Q","article-title":"HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination","volume":"92","author":"Kaufmann","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.arcmed.2009.07.003_bib71","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.1128\/JVI.73.7.5402-5410.1999","article-title":"Induction of human papillomavirus-specific CD4+ and CD8+ lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer","volume":"73","author":"Santin","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.arcmed.2009.07.003_bib72","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00432-003-0463-5","article-title":"Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients","volume":"129","author":"Ferrara","year":"2003","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.arcmed.2009.07.003_bib73","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1056\/NEJM200205303462219","article-title":"Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer","volume":"346","author":"Santin","year":"2002","journal-title":"N\u00a0Engl J Med"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440909001283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440909001283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:37:12Z","timestamp":1759261032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440909001283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0188440909001283"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2009.07.003","relation":{},"ISSN":["0188-4409"],"issn-type":[{"type":"print","value":"0188-4409"}],"subject":[],"published":{"date-parts":[[2009,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Therapeutic Vaccine: Is it Feasible?","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2009.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 IMSS. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}